Company / Return on Equity (ROE)
ADMA Biologics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
30.8%
FY2025
5-year range
-81.2% / 56.6%
FY2021-FY2025
Trend
-45.7%
vs FY2024
Sector context
#16 of 190
Health Care
What the data says
Among 190 Health Care companies, ADMA Biologics, Inc. is in the top 8% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 8 years, ranging from -332.5% in FY2018 to 56.6% in FY2024.
Based on SEC 10-K filings.
30.8% in FY2025 with a 5-year CAGR of +116.6%. Top quartile in the Health Care sector.
Improved from -20.9% to 30.8% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +112.0pp
- 5-Year Change
- +116.6pp
- 10-Year Change
- -
Sector benchmark
+161.0% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 45.7% year-over-year.
- Currently 81.2pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 30.8% | -45.7% |
| FY2024 | 56.6% | +371.1% |
| FY2023 | -20.9% | +74.3% |
| FY2022 | -81.2% | -60.0% |
| FY2021 | -50.7% | +40.9% |
| FY2020 | -85.8% | +53.4% |
| FY2019 | -184.3% | +44.6% |
| FY2018 | -332.5% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026